AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
AgNovos Healthcare is focused on developing novel treatments to address bone disease, a crucial quality-of-life issue
AgNovos is recruiting for clinical trial studies in Europe. If you are a post-menopausal woman with osteoporosis and are interested in learning more about the study, please click below.
OSSURE® LOEP® (Local Osteo-Enhancement Procedure) is a targeted approach to address local bone loss, including loss due to osteoporosis.
The Agnovos Way
AgNovos is committed to act in a way that is consistent with our core values and commitment to helping patients and physicians confronting bone disease. We will continually pursue new discoveries, technologies, and programs that improve bone health and education so that we can help families, communities, and the world move forward with more confidence.
Our employees have the opportunity to grow professionally and personally as they work to help the company through each exciting phase of its growth.
Our talented, dedicated employees bring far more to the company than just their experience and expertise. They are deeply committed to our core goal: helping patients maintain their mobility, independence, and quality of life.